Viravaxx AG – project for COVID-19

Viravaxx AG, a clinical stage biopharmaceutical company based in Vienna, Austria, announced today that it has launched a project for combating COVID-19 together with the Medical University of Vienna.
By: PR&D
 
VIENNA - April 21, 2020 - PRLog -- In this project an integrated immunodiagnostic and vaccination platform for COVID-19 will be created. Based on the partners' novel microchip technology platform, a microarray is composed, on which the structural proteins of the SARS-CoV-2-virus in glycosylated and non-glycosylated form as well as certain relevant fragments of the proteins and a library of overlapping peptides from virus proteinsare represented. This microarray – thereby covering the whole proteome of the virus – allows high resolution mapping of antigenic determinants eliciting an immune response following infection.

Furthermore, an ELISA assay capable of analyzing the interaction of the SARS-CoV-2 spike protein with its receptor is established. In a clinical study, which has already received ethics approval and will start very soon, sera from convalescent COVID-19 patients will be tested for virus neutralization capacity and for epitope mapping. 200 patients with mild and 200 patients with severe course of the disease will be enrolled and compared to 200 healthy controls.

These data and pseudonymized clinical records using machine learning algorithms contributed by the Technical University of Munich (Prof. Jan Baumbach) will be correlated to derive antibody signatures. Both tests together are expected to deliver reliable results about the development of protective immunity.

These signatures and the identification of epitopes eliciting a virus neutralizing antibody response will enable the design of vaccine candidates using our proprietary PCFiT- (peptide-carrier-fusion) platform. These vaccines will be tested for immunogenicity in animal models, and the immune response will be analyzed with our microarray and the neutralization ELISA. They will subsequently be moved to clinical testing in the shortest possible timeframe.

Viravaxx AG

Rainer Henning, CEO

Mariannengasse 14/9

1090 Vienna, Austria

T +43-1-7966-296-100

F +43-1-7966-296-222

M +43-664-415-9511

E r.henning@viravaxx.com

W www.viravaxx.eu

Distribution

PR&D – Public Relations for Research & Education

Dr. Barbara Bauder

Mariannengasse 8

1090 Vienna / Austria

T +43  1 505 70 44

M +43 664 1576350

E bauder@prd.at

W http://www.prd.at/ (http://www.viravaxx.eu/)

Contact
PR&D – Public Relations for Research & Education
***@prd.at
End
Email:***@prd.at Email Verified
Tags:COVID-19
Industry:Health
Location:Vienna - Vienna - Austria
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
PR&D - Public Releations for Research & Education PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share